Abiraterone Acetate (sold under brand names such as Zytiga and Yonsa) is an advanced oral, targeted endocrine therapeutic agent categorized as a CYP17 inhibitor (androgen synthesis inhibitor). It represents a major milestone in urologic oncology, providing an effective treatment option for patients with advanced forms of prostate cancer.
By blocking androgen production at all three key sources in the body—the testes, the adrenal glands, and the tumor tissue itself—Abiraterone Acetate starves prostate cancer cells of the male hormones (androgens) they require to grow and survive.
What is Abiraterone Acetate Used For?
Abiraterone Acetate is indicated for male patients for the treatment and management of advanced prostate cancer in combination with a corticosteroid (Prednisone or Methylprednisolone):
• Metastatic Castration-Resistant Prostate Cancer (mCRPC): For prostate cancer that has spread to other parts of the body and no longer responds to medical or surgical treatments that lower testosterone.
• Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC): For newly diagnosed, high-risk metastatic prostate cancer that still responds to hormone therapy.
How Does Abiraterone Acetate Work?
Prostate cancer cells rely heavily on androgens (such as testosterone) to signal cell proliferation and survival. While standard androgen deprivation therapy (ADT) stops androgen production in the testes, other sources continue to produce lower levels of male hormones.
Abiraterone Acetate operates through a precise molecular mechanism:
• CYP17 Enzyme Inhibition: Abiraterone Acetate is converted in vivo to abiraterone, a selective, irreversible inhibitor of the CYP17 enzyme complex (which possesses 17α-hydroxylase and 17,20-lyase activity).
• Tri-Source Androgen Suppression: The CYP17 enzyme complex is essential for androgen biosynthesis across three critical tissues: the testicular Leydig cells, the adrenal cortex, and intra-tumoral prostate tissue.
• Prostate Cancer Regression: By blocking CYP17, Abiraterone Acetate reduces serum testosterone and other circulating androgens to undetectable levels, halting androgen receptor-driven tumor growth.
Benefits of Abiraterone Acetate
• Extended Overall Survival: Clinically proven in large randomized trials (e.g., COU-AA-301, COU-AA-302, LATITUDE) to extend overall survival (OS) and delayed disease progression in patients with metastatic prostate cancer.
• Comprehensive Hormone Suppression: Suppresses androgen production at the source (including adrenal glands and microenvironment within the tumor itself) beyond standard castration methods.
• Convenient Daily Oral Dosing: Delivered as once-daily tablets, eliminating the need for frequent chemotherapy clinic visits.
Available Strengths & Formulations
Abiraterone Acetate is manufactured in two primary pharmaceutical formulations (which are not bioequivalent and have different dosing requirements):
Standard Formulation (e.g., Zytiga and generics)
• 250 mg film-coated tablets
• 500 mg film-coated tablets
Sub-micronized Formulation (e.g., Yonsa)
• 125 mg film-coated tablets (formulated for enhanced absorption)
Recommended Dosage & Administration
Abiraterone Acetate must always be co-administered with a corticosteroid (such as Prednisone or Methylprednisolone) to compensate for decreased cortisol production and prevent mineralocorticoid excess.
Standard Adult Dosage Guidelines
• Standard Formulation (Zytiga / Generic): 1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily, administered together with Prednisone 5 mg taken orally once or twice daily.
• Sub-micronized Formulation (Yonsa): 500 mg (four 125 mg tablets) orally once daily, administered together with Methylprednisolone 4 mg taken orally twice daily.
This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda - FDA
Crucial Administration Rules
• Food Effect (Standard Formulations): Standard Abiraterone Acetate (Zytiga) must be taken on an empty stomach. Do not eat any food for at least 2 hours before and at least 1 hour after taking the dose. Taking standard abiraterone with food increases systemic drug exposure up to 10-fold, leading to unpredictable toxicity. (Note: Yonsa may be taken with or without food).
• Swallow Whole: Swallow tablets whole with water. Do not crush, break, or chew them.
• Steroid Compliance: Never stop taking the prescribed co-administered corticosteroid without consulting your oncologist, as sudden withdrawal can lead to adrenal insufficiency.
Missed Dose
• If a dose is missed, skip the missed dose and resume your regular daily schedule the next day. Do not take two doses at once to make up for a missed dose.
Common & Serious Side Effects
While well-tolerated, Abiraterone Acetate alters hormone levels and can cause distinct side effects:
• Common Side Effects:
o Mineralocorticoid Excess Symptoms: Fluid retention/edema (swollen ankles/legs), hypertension (high blood pressure), and hypokalemia (low blood potassium).
o General Effects: Fatigue, hot flashes, joint pain/swelling (arthralgia), diarrhea, nausea, cough, and upper respiratory tract infections.
• Serious Warnings & Precautions:
o Hepatotoxicity: Can cause elevated liver enzymes (ALT, AST) and total bilirubin, which can lead to liver failure. Dose adjustments or therapy interruption may be necessary.
o Mineralocorticoid Excess: Due to CYP17 inhibition, elevated mineralocorticoid production can trigger severe hypertension, severe hypokalemia, and cardiac arrhythmias.
o Adrenocortical Insufficiency: Inhibition of CYP17 reduces baseline cortisol synthesis. Discontinuing the accompanying steroid or experiencing unusual physical stress can cause adrenal crisis.
o Hypoglycemia: Severe low blood sugar has been reported in patients with pre-existing diabetes taking certain diabetes medications (like pioglitazone or repaglinide).
Drug Interactions
Abiraterone Acetate is metabolized by liver enzymes (CYP3A4) and inhibits CYP2D6:
• CYP3A4 Inducers: Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) decrease Abiraterone blood levels, reducing drug effectiveness.
• CYP2D6 Substrates: Abiraterone increases blood levels of medications metabolized by CYP2D6 (such as dextromethorphan, thioridazine, or atomoxetine).
• Radium Ra 223 Dichloride: Combining Abiraterone Acetate plus Prednisone/Prednisolone with Radium Ra 223 dichloride is not recommended due to a documented increase in bone fractures and mortality.
Handling & Embryo-Fetal Toxicity
• Embryo-Fetal Hazard: Abiraterone Acetate can cause severe fetal harm or pregnancy loss. It is strictly contraindicated in females who are pregnant or planning to become pregnant.
• Handling Precautions: Women who are pregnant or may become pregnant must not handle broken or crushed Abiraterone Acetate tablets without protection (gloves), as the active substance can be absorbed through the skin.
• Male Contraception Requirements: Male patients with female partners of reproductive potential must use effective contraception during treatment and for 3 weeks after the final dose.
Monitoring During Treatment
Clinical management requires regular ongoing monitoring:
• Liver Function Tests (LFTs): Baseline measurement of serum transaminases (ALT, AST) and bilirubin every 2 weeks for the first 3 months, and monthly thereafter.
This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda - FDA
• Blood Pressure, Potassium, & Fluid Retention: Monthly assessments of blood pressure, serum potassium levels, and clinical signs of edema.
• Prostate-Specific Antigen (PSA) & Imaging: Periodic tracking of serum PSA levels and periodic bone/CT scans to measure treatment response.
Generic Abiraterone Acetate
Generic formulations of Abiraterone Acetate are globally available and approved by major health authorities:
• Cost-Effectiveness: Provides an affordable alternative compared to brand-name Zytiga.
• Therapeutic Bioequivalence: Contains the identical active pharmaceutical ingredient (API) and delivers therapeutic outcomes identical to the original brand.
Frequently Asked Questions (FAQs)
Why do I need to take Prednisone alongside Abiraterone Acetate?
Abiraterone inhibits the enzyme CYP17, which reduces your body's natural production of cortisol. Taking daily Prednisone replaces this missing cortisol and suppresses excess adrenocorticotropic hormone (ACTH), preventing complications like high blood pressure, low potassium, and fluid retention.
Why is it critical to take standard Abiraterone (Zytiga) on an empty stomach?
Taking standard Abiraterone with food dramatically increases how much drug your body absorbs. This sudden surge in drug concentration can lead to severe side effects, including severe liver toxicity and cardiac complications.
Can women or children handle Abiraterone Acetate?
No. Abiraterone Acetate is not indicated for women or pediatric populations. Pregnant women should avoid touching or handling broken tablets due to the risk of skin absorption causing harm to an unborn baby.
Important Safety Information
This document is intended strictly for educational purposes and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist or healthcare provider regarding treatment decisions or medication adjustments.
References
• U.S. Food and Drug Administration (FDA) Prescribing Information (Zytiga / Yonsa / Abiraterone Acetate)
This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda - FDA
• National Center for Biotechnology Information (NCBI) StatPearls: Abiraterone Acetate
• American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines for Prostate Cancer
• European Association of Urology (EAU) Guidelines on Prostate Cancer
Contact Us
Are you searching for Generic Abiraterone Acetate, wholesale pricing structures, global availability, or export documentation?
Our expert team is fully equipped to guide you through trusted manufacturer selections, product availability, international licensing, and country-specific import regulations. Contact us today to learn more.
What is Abiraterone Acetate?
Abiraterone Acetate (sold under brand names such as Zytiga and Yonsa) is an advanced oral, targeted endocrine therapeutic agent categorized as a CYP17 inhibitor (androgen…
